Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting annually. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). Additionally, the RSUs include provisions for immediate full vesting in case of employment termination under specific conditions following a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale specializzata in terapie oncologiche, ha annunciato la concessione di 666 unit脿 azionarie vincolate (RSU) a due nuovi dipendenti a partire dal 30 giugno 2025.
Le assegnazioni di RSU, concesse nell'ambito del Piano di Incentivazione Azionaria 2022 della Societ脿, matureranno in tre anni, con un 33 1/3% che matura annualmente. Le assegnazioni sono state effettuate in conformit脿 con la Regola di Quotazione Nasdaq 5635(c)(4). Inoltre, le RSU prevedono la maturazione immediata e completa in caso di cessazione del rapporto di lavoro in determinate condizioni successive a un evento di cambio di controllo.
Karyopharm Therapeutics (Nasdaq: KPTI), una empresa farmac茅utica en etapa comercial centrada en terapias contra el c谩ncer, ha anunciado la concesi贸n de 666 unidades restringidas de acciones (RSU) a dos empleados reci茅n contratados a partir del 30 de junio de 2025.
Las concesiones de RSU, otorgadas bajo el Plan de Incentivos de Acciones por Inducci贸n 2022 de la Compa帽铆a, se consolidar谩n durante tres a帽os, con un 33 1/3% consolid谩ndose anualmente. Las concesiones se realizaron de acuerdo con la Regla de Listado Nasdaq 5635(c)(4). Adem谩s, las RSU incluyen disposiciones para la consolidaci贸n inmediata y total en caso de terminaci贸n del empleo bajo condiciones espec铆ficas tras un evento de cambio de control.
Karyopharm Therapeutics (雮橃姢雼�: KPTI)電� 鞎� 旃橂鞐� 欷戩爯鞚� 霊� 靸侅梾 雼硠鞚� 鞝滌暯 須岇偓搿滌劀, 2025雲� 6鞗� 30鞚茧秬搿� 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 666臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟.
鞚� RSU 氤挫儊鞚� 須岇偓鞚� 2022雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 攵�鞐悩氅�, 3雲勳棎 瓯胳硱 毵る厔 33 1/3%鞌� 氩犾姢韺�霅╇媹雼�. 鞚� 攵�鞐姅 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�. 霕愴暅, RSU鞐愲姅 歆�氚瓣秾 氤�瓴� 靷贝 頉� 韸轨爼 臁瓣贝 頃橃棎靹� 瓿犾毄 膦呺 鞁� 歃夓嫓 鞝勳暋 氩犾姢韺呺悩電� 臁绊暛鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Karyopharm Therapeutics (Nasdaq : KPTI), une soci茅t茅 pharmaceutique en phase commerciale sp茅cialis茅e dans les th茅rapies contre le cancer, a annonc茅 l鈥檃ttribution de 666 unit茅s d鈥檃ctions restreintes (RSU) 脿 deux nouveaux employ茅s 脿 compter du 30 juin 2025.
Les attributions de RSU, accord茅es dans le cadre du Plan d鈥橧ncitation 脿 l鈥橝ctionnariat 2022 de la Soci茅t茅, seront acquises sur une p茅riode de trois ans, avec 33 1/3 % acquis chaque ann茅e. Les attributions ont 茅t茅 effectu茅es conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4). De plus, les RSU comprennent des dispositions pour une acquisition imm茅diate et totale en cas de cessation d鈥檈mploi dans des conditions sp茅cifiques suite 脿 un 茅v茅nement de changement de contr么le.
Karyopharm Therapeutics (Nasdaq: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase mit Schwerpunkt auf Krebstherapien, hat die Gew盲hrung von 666 Restricted Stock Units (RSUs) an zwei neu eingestellte Mitarbeiter zum 30. Juni 2025 bekannt gegeben.
Die RSU-Zuweisungen, die im Rahmen des Inducement Stock Incentive Plans 2022 des Unternehmens gew盲hrt wurden, werden 眉ber drei Jahre mit einer j盲hrlichen Vesting-Rate von 33 1/3% freigegeben. Die Zuweisungen erfolgten gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4). Zus盲tzlich enthalten die RSUs Bestimmungen f眉r eine sofortige vollst盲ndige Vesting bei Beendigung des Arbeitsverh盲ltnisses unter bestimmten Bedingungen nach einem Kontrollwechselereignis.
- None.
- None.
Each RSU award will vest over three years, with 33 1/
In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm聽has聽been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis.聽Karyopharm's lead compound and first颅in颅class, oral exportin 1 (XPO1) inhibitor, XPOVIO庐 (selinexor), is approved in the
XPOVIO庐 and NEXPOVIO庐 are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:
SOURCE Karyopharm Therapeutics Inc.
FAQ
What type of stock awards did Karyopharm Therapeutics (KPTI) grant to new employees in June 2025?
What is the vesting schedule for Karyopharm's (KPTI) June 2025 RSU grants?
Under what conditions can Karyopharm's (KPTI) June 2025 RSU grants become immediately exercisable?
What is the purpose of Karyopharm's (KPTI) June 2025 RSU grants?
